Sign up USA
Proactive Investors - Run By Investors For Investors

Regen Biopharma applies for clinical trial of immunotherapy treatment

The US regulator will now decide whether the drug is safe to progress human trials.
Regen Biopharma applies for clinical trial of immunotherapy treatment
tCellVax comprises a patient’s own immune cells, which are then activated to attack cancerous cells.

Regen BioPharma Inc (OTCBB:RGBP) has applied to the US Food and Drug Administration for Investigational New Drug status for its tCellVax immunotherapy treatment for cancer.

The US regulator will now decide whether the drug is safe to progress human trials.

Regen said preclinical data had indicated the gene silencing approach was “dramatically effective” at stimulating the body’s immune response.

"Because tCellVax is a personalized cell therapy product aimed at activating the immune system of patients with cancer, we are excited to potentially have a product to deliver to patients who at the moment have no other options," said David Koos Regen BioPharma’s chief executive.

“Using siRNA to silence NR2F6 activity in human immune cells is dramatically effective at stimulating the type of immune response associated with known checkpoint inhibitors.” 

tCellVax comprises a patient’s own immune cells, which are then activated to attack cancerous cells.

“Regen and other groups have shown the cells in tCellVax are highly active and secrete the same cytokines that immune cells known to kill cancer cells do.”

The NR2F6 gene is clearly playing a role as a very potent immune checkpoint, he said, and tCellVax is designed to inhibit this protein.

Regen’s current focus is to use gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

PhilW.jpg


Register here to be notified of future RGBP Company articles
View full RGBP profile

Regen BioPharma Timeline

Related Articles

CancerHeadline.jpg
March 29 2016
The company said it is now testing the Proton Source for its LIGHT system in situ in France.
AZN2.jpg
March 31 2016
Amryt Pharmaceuticals will join the London market in a deal that values it at £29.6mln. A share placing, meanwhile, will bring in £10mln to be used to develop the company’s lead treatment for a rare skin disorder.
AZN3.jpg
March 23 2016
Douglas Carrara has joined as vice president of Global Marketing and Commercial Operations, while Tony Saporito has been brought in as vice president of US Sales and Distribution.
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC